Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Exicure, Inc. (XCUR : NSDQ)

• Company Description    Exicure Inc. is a clinical-stage biotechnology company. It is engaged in developing therapeutics for immuno-oncology, inflammatory diseases and genetic disorders based on our proprietary Spherical Nucleic Acid technology. Exicure Inc. is based in IL, United States. Number of Employees: 7

• Price / Volume Information    Yesterday's Closing Price: $7.28 Daily Weekly Monthly 20 Day Moving Average: 252,707 shares Shares Outstanding: 6.32 (millions) Market Capitalization: $45.99 (millions) Beta: 3.57 52 Week High: $36.00 52 Week Low: $1.44 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -19.02% -22.05% 12 Week -13.74% -27.45% Year To Date -46.74% -50.13%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 400 Seaport Court Suite 102 - Redwood City,CA 94063 USA ph: 847-673-1700 fax: - ir@exicuretx.com http://www.exicuretx.com

• General Corporate Information    Officers Andy Yoo - Chief Executive Officer;President and Director Seung Ik Baik - Chief Financial Officer; and Director Joshua Miller - Chief Accounting Officer Minwoo Kang - Director Dongho Lee - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 30205M309 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/12/25 Share - Related Items Shares Outstanding: 6.32 Most Recent Split Date: 8.00 (0.20:1) Beta: 3.57 Market Capitalization: $45.99 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/12/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 4.04 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 10.00% vs. Previous Quarter: 86.73% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/25 - - 03/31/25 - -219.60 12/31/24 - -319.72 ROA 06/30/25 - - 03/31/25 - -82.03 12/31/24 - -82.41 Current Ratio 06/30/25 - - 03/31/25 - 2.91 12/31/24 - 4.45 Quick Ratio 06/30/25 - - 03/31/25 - 2.91 12/31/24 - 4.45 Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - - 12/31/24 - -1,938.60 Book Value 06/30/25 - - 03/31/25 - 1.80 12/31/24 - 1.12 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00

Powered by Zacks Investment Research ©